wersja polska  
Mediton - Publishing House
Start page  Journals  Books  Conferences  News  Mediton  Contact   
   Journals
print this
   Allergy Asthma Immunology - archive  

Allergy Asthma Immunology
     Archive
     Editorial staff
     Editorial board
     For authors
     Subscription
Otorhinolaryngology
Allergology Review



 Search in articles:
  Authority of Polish Society of Allergology




vol 20. no 4. December 2015  
 TABLE OF CONTENT

 Review articles
Tiotropium – new agent in asthma therapy
Maciej Kupczyk

Tiotropium represents the only long-acting antimuscarinic drug registered
for the treatment of asthma. The latest 2015 GINA guidelines recommend
tiotropium as a second-line treatment in adult patients with
asthma at step 4 and 5, in whom the disease is not well managed despite
current therapy (≥800 μg of budesonide and LABA) and who therefore
experience frequent exacerbations. Numerous clinical trials proved that
tiotropium improves lung function, prolongs the exacerbation–free period
and decreases the number of exacerbations (31% decrease vs placebo)
in asthma patients. Respimat soft mist inhaler guarantees high lung
deposition of tiotropium. In conclusion, tiotropium may be considered
an interesting alternative as adjunctive therapy for asthma patients who
remain uncontrolled despite current treatment.

keywords: tiotropium, terapia astmy, zaostrzenia astmy, tiotropium, asthma therapy, asthma exacerbations

pages: from 239 to 241



estimated time of download (66 kB)
broadband speed:561282565121024[kbps]
time:145322[sec]


You need to have Adobe Acrobat Reader to view the PDF file. It's free. If you don't have the Adobe Acrobat Reader plugin yet, you can get it HERE.


Start page | Journals | Books | Conferences | News | Mediton | Contact

Copyright © 1996-2020 Mediton Publishing House | All rights reserved.